TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03619343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)
Description: When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)
Description: When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
Study: NCT03004222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 ml of 0.5% Bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT03718182

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: vitamin D3 daily oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: vitamin D3 daily oral supplement
Study: NCT04962542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ventilation
Description: low volume positive pressure ventilation is better than continuous positive airway pressure and passive deflation on arterial oxygenation and PPD after CPB in pediatrics undergoing cardiac surgeries for non-cyanotic congenital heart defects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ventilation
Description: low volume positive pressure ventilation is better than continuous positive airway pressure and passive deflation on arterial oxygenation and PPD after CPB in pediatrics undergoing cardiac surgeries for non-cyanotic congenital heart defects.
Study: NCT03959540

Intervention type: DRUG
Intervention: Opicapone
Description: Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.

Intervention type: DRUG
Intervention: Levodopa (L-DOPA) + Standard care
Description: Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
Study: NCT03670927

Intervention type: OTHER
Intervention: Environmental, occupational and lifestyle-related exposures
Description: A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed

Intervention type: OTHER
Intervention: Environmental, occupational and lifestyle-related exposures
Description: A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
Study: NCT02869061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral bladder neck resection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADRC
Description: Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
Study: NCT01886716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Attention Training
Description: Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Attention Training
Description: Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
Study: NCT03959540

Intervention type: DRUG
Intervention: Levodopa (L-DOPA) + Standard care
Description: Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
Study: NCT03080220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astym
Description: therapeutic massage instrument

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stick
Description: massage instrument

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Massage
Description: massage instruments
Study: NCT02775058

Intervention type: DEVICE
Intervention: synergoss Pxx
Description: dental grafting
Study: NCT04522245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight; mobile behavior change program for weight loss.
Description: The mobile cognitive behavior change program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.~There are 52 weeks of curriculum with 1-3 articles to read per day. Users are requested to perform weight logging once daily and food logging after each meal. Users are assigned human coaches and are able to interact with them via in-app messaging or phone communication. Users are also assigned to support groups via in-app messaging.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Control
Description: Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
Study: NCT01706809

Intervention type: OTHER
Intervention: blood sampels from vena rectalis superior and vena cubiti
Study: NCT01237080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fastrach
Description: The Fastrach is an intubation laryngeal mask.
Study: NCT02531490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyldopa
Study: NCT00566722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
Study: NCT05578794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Straining types
Description: Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Straining types
Description: Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Straining types
Description: Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
Study: NCT01272024

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Education
Description: Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
Study: NCT00645827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IICE Dosing
Description: Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare Provider dosing
Description: Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
Study: NCT04411017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Colonoscopy
Study: NCT00676650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg BID, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 37.5 mg/day, oral, administered on a continuous daily dosing regimen
Study: NCT01886716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Attention Training
Description: Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Attention Training
Description: Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Training
Description: Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
Study: NCT00850161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspart
Description: Meal-time insulin. Administered subcutaneously based on routine clinical therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasulin™
Description: 100 IU(2 puffs in each nostril)
Study: NCT04217785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genteal lubricant gel
Description: Genteal lubricant gel (2 drops per day, for 8 weeks)
Study: NCT04007887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult education program
Description: A 10-hour program embodying major adult education principles, designed to achieve cognitive involvement of patients in their treatment
Study: NCT04145687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg tid
Study: NCT02993497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared camera
Description: In patients undergoing spinal anesthesia, the respiratory parameters are measured using an Infrared camera.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RVM(Respiratory Volume Monitor)
Description: In patients undergoing spinal anesthesia, the respiratory parameters are measured using an RVM(Respiratory Volume Monitor).
Study: NCT01750996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families
Description: Behavioural intervention
Study: NCT01085487

Intervention type: DRUG
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: Women using Mirena for treatment of menorrhagia
Study: NCT00090051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous repeating dose
Study: NCT02219555

Intervention type: DRUG
Intervention: Steroid Injection
Description: volume and specific steroid drug will be based on the recommendation of the treating clinician
Study: NCT01019174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
Study: NCT01254539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laminectomy and bone marrow stem cells transplantation
Description: Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal infusion of autologous bone marrow stem cells
Description: Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal infusion of placebo (saline solution).
Description: Patients were infused 2 ml of saline solution
Study: NCT00615160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Description: PTK-ZK capsules taken orally with a daily flat dose of 1250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Description: PTK-ZK capsules taken orally with a daily flat dose of 1250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine 850 mg/m² on day 1 q4w
Study: NCT03574389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib
Description: suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
Study: NCT03593278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-246475
Description: Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
Study: NCT00625105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Biofeedback
Study: NCT02399566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib, Pemetrexed
Description: followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib, Pemetrexed
Description: followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
Study: NCT01085487

Intervention type: DRUG
Intervention: Hormonal treatment
Description: Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
Study: NCT00090051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous repeating dose
Study: NCT00803374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
Study: NCT02266914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography driver
Description: A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
Study: NCT02688712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Small molecule inhibitor of transforming growth factor-beta signaling pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Antimetabolite chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Antimetabolite chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor specific mesorectal excision
Description: Tumor specific mesorectal excision
Study: NCT02219555

Intervention type: PROCEDURE
Intervention: Carpel Tunnel surgery
Description: Standard of care carpel tunnel surgery
Study: NCT03696173

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT00803374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
Study: NCT03954041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB093
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB093
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT00638807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule once daily with morning meal for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo for 6 weeks
Study: NCT02777736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: i.v. or intrathecal CNS prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: i.v. or intrathecal CNS prophylaxis
Study: NCT01655264

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based self training exercises for weak upper extremity
Description: Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
Study: NCT03054454

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Podiatry
Description: Podiatry treatments and care from the multidisciplinary team.
Study: NCT01085487

Intervention type: DRUG
Intervention: Antifibrinolytic treatment
Description: Antifibrinolytic treatment (such as tranexamic acid)
Study: NCT04006860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHC014748M Capsules
Description: SHC014748M Capsules: 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHC014748M Capsules
Description: SHC014748M Capsules: 200mg